MEC-2

Specification
Technical Resources
Recommended Products
Publications

Cat.No.

CSC-C0511

Description

Established in 1994 from the peripheral blood of a 62-year-old Caucasian man with chronic B cell leukemia (B-CLL in prolymphocytoid transformation to B-PLL) prior to therapy; serial sister cell line of MEC-1

Species

Human

Source

chronic B cell leukemia

Recommended Medium

90% SuperCult® IMDM + 10% h.i. FBS.

Culture Properties

suspension

Morphology

polymorphic cells growing in suspension in large clumps; clumps can easily be segregated

Karyotype

Human flat-moded hypertriploid karyotype with 7% polyploidy - 75-80<3n>XX/XXY, -6, -9, -10, +11, +12, -13, +15, -17, -21, +10mar - add(X)(p22)x2, inv(12)(?p12.2?q24.1)x2, add(18)(q2?1) - karyotypically distinct from MEC-1 (as reported)

Quality Control

Mycoplasma: negative in microbiological culture, PCR assays
Immunology: CD3 -, CD10 -, CD13 -, CD19 +, CD20 +, CD34 -, CD37 +, cyCD79a +, CD80 +, CD138 +, HLA-DR +, sm/cyIgG -, sm/cyIgM +, sm/cykappa +, sm/cylambda -
Viruses: PCR: EBV +, HBV -, HCV -, HIV

Storage and Shipping

Frozen with 70% medium, 20% FBS, 10% DMSO at about 5 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Product Sheets

Datasheet